Analysts Set Lemonade, Inc. Price Target at $68.75

Nine research firms currently cover the insurance tech company's stock.

Apr. 15, 2026 at 5:50am

Got story updates? Submit your updates here. ›

An extreme close-up of the intricate, heavy-duty machinery and gears that make up the internal workings of a large industrial bank vault, conveying a sense of the physical power and security of financial institutions.The complex financial infrastructure that underpins the insurance industry is a key focus for analysts evaluating Lemonade's growth potential.NYC Today

Shares of Lemonade, Inc. (NYSE:LMND) have been assigned a consensus 'Hold' rating from nine research firms covering the stock, with an average 12-month price target of $68.75. The analysts' views on the company's prospects are mixed, with three 'Sell' recommendations, one 'Hold', and five 'Buy' ratings.

Why it matters

Lemonade is a high-profile insurtech startup that has disrupted the traditional insurance industry with its AI-powered, digital-first approach. Analysts' assessments of the company's stock performance and future outlook provide valuable insights into investor sentiment and the competitive landscape for innovative insurance providers.

The details

The analysts' price targets for Lemonade range from $65 to $92, with the average set at $68.75. Morgan Stanley recently upgraded the stock to 'Overweight' and raised the price target to $85, while Piper Sandler set a $65 target. Other firms like Weiss Ratings and Citigroup have also weighed in with their assessments of the company's prospects.

  • Lemonade reported its latest quarterly earnings on February 18, 2026.
  • The analysts' ratings and price targets were issued in the past 12 months.

The players

Lemonade, Inc.

A New York-based technology-driven insurance carrier that leverages artificial intelligence and behavioral economics to streamline the purchase and management of policies.

Morgan Stanley

A global financial services firm that recently upgraded Lemonade's stock to 'Overweight' and raised the price target.

Piper Sandler

An investment bank that set a $65 price target on Lemonade's stock.

Weiss Ratings

A financial research firm that issued a 'Sell (d-)' rating on Lemonade's stock.

Citigroup

A multinational investment bank that issued an 'Outperform' rating on Lemonade's stock.

Got photos? Submit your photos here. ›

What’s next

Investors will be closely watching Lemonade's future financial performance and any updates from the company or analysts on its growth prospects and competitive positioning.

The takeaway

Lemonade's mixed analyst ratings and price targets reflect the uncertainty and high expectations surrounding the insurtech disruptor. As the company continues to innovate and scale, its ability to deliver on financial targets and maintain a competitive edge will be crucial in determining its long-term success.